Short talks Pharmacology 3
Cardiac pharmacology and treatment

Programme

• 09:00 – 09:15 10 Min. 5 Min.

  • Oral presentation
  • 09

  microRNA-21 inhibition prevents adverse cardiac remodeling and dysfunction following myocardial infarction, an effect driven by macrophages.

  • Ileana Duran Fernandez (Munich / DE)

   Cardiac pharmacology, Immunopharmacology / inflammation / anti-infectives
• 09:15 – 09:30 10 Min. 5 Min.

  • Oral presentation
  • 10

  Characterization of molecular and ventricle-specific events in cardiac hypertrophy and subsequent failure using RNAseq and smRNA FISH in an animal model of slowly progressing disease

  • Liane Jurida (Gießen / DE)

   Cardiac pharmacology, Disease models, drug development
• 09:30 – 09:45 10 Min. 5 Min.

  • Oral presentation
  • 11

  The Ca²⁺ re-uptake inhibitor PLN^R9C perturbs cardiac excitation/contraction coupling with implication on mitochondria and SR/ER

  • Theresa Brand (Würzburg / DE)

   Cardiac pharmacology, Signal transduction and second messengers
• 09:45 – 10:00 10 Min. 5 Min.

  • Oral presentation
  • 12

  NO-induced cGMP generated in fibroblasts increases cardiac cAMP and phospholamban phosphorylation.

  • Lukas Menges (Bochum / DE)

   Cardiac pharmacology, Signal transduction and second messengers
• 10:00 – 10:15 10 Min. 5 Min.

  • Oral presentation
  • 13

  Differential regulation of MMPs, apoptosis and cell proliferation by the cannabinoid receptors CB1 and CB2 in vascular smooth muscle cells and cardiac myocytes

  • Bettina Greiner (Berlin / DE)

   Cardiac pharmacology, G-protein coupled receptors
• 10:15 – 10:30 10 Min. 5 Min.

  • Oral presentation
  • 14

  ADAM10 is upregulated in human heart failure and its pharmacological as well genetic inhibition abolishes CX3CL1-dependent leucocyte infiltration and improves survival and cardiac function after infarction

  • Erik Klapproth (Dresden / DE)

   Cardiac pharmacology, Disease models, drug development